CASI Pharmaceuticals, Inc. (CASIF): Total Liabilities
$62.93M
As of 2025-12-31
+29.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.93M | +21.4% | 2026-05-15, Balance as of period end |
| 2024-12-31 | $51.82M | +1.4% | 2026-05-15, Balance as of period end |
| 2023-12-31 | $51.10M | +74.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $29.30M | -3.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $30.34M | n/a | 2023-04-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $7.11M | +1.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
Compare CASIF, SCYX, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗